Clinical Edge Journal Scan

Fatigue impairs general health outcomes in PsA


 

Key clinical point: A substantial proportion of patients with psoriatic arthritis (PsA) reported fatigue, and the degree of fatigue had a significant impact on their disease severity and physical functionality.

Major finding: The majority of patients with PsA (78.3%) reported fatigue. Patients with higher fatigue scores reported more severe disease, greater pain levels, and higher tender/swollen joint count (all P < .001). Higher fatigue scores were associated with worse physical functioning and higher overall work impairment (both P < .001).

Study details: Findings are from an analysis of an independent, cross-sectional, multinational, real-world survey, Adelphi Real World Spondyloarthritis (SpA) IV Disease Specific Programme, including 831 patients with PsA.

Disclosures: The Adelphi SpA IV Disease Specific Programme was funded by Janssen. Three authors declared being employees of Janssen and shareholders of Janssen/Johnson & Johnson. Four authors declared being employees of Adelphi Real World. Other authors declared receiving grants of serving as consultants for several sources, including Janssen.

Source: Gossec L et al. Impact of fatigue on health-related quality of life and work productivity in psoriatic arthritis: Findings from a real-world survey. J Rheumatol. 2022 (Jul 15). Doi: 10.3899/jrheum.211288

Recommended Reading

FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
MDedge Rheumatology
PsA: Bimekizumab is well tolerated and effective in the long-term
MDedge Rheumatology
Golimumab effective as second-line anti-TNFα treatment in the real-world
MDedge Rheumatology
Nail disease and dactylitis influence treatment response in patients receiving etanercept or methotrexate
MDedge Rheumatology
Nail dystrophy predicts response to secukinumab in PsA patients with axial manifestations
MDedge Rheumatology
Clinically meaningful improvement in PRO with risankizumab vs placebo in PsA
MDedge Rheumatology
Robust and consistent improvement in HRQoL with guselkumab
MDedge Rheumatology
Long-term safety and efficacy of risankizumab in PsA
MDedge Rheumatology
PsA remission depends on patient perception and is multidimensional
MDedge Rheumatology
Elevated IL-23 levels associated with psychiatric disorders in PsA
MDedge Rheumatology